TerminatedNot Applicable

Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome

Stopped: Low Enrollment

United States20 participantsStarted 2019-09-30

Plain-language summary

The purpose of this study is to determine if peripheral nerve ultrasound can be used as a supplemental tool to diagnose Guillain-Barre syndrome (GBS) in the acute setting and aid in prognostication.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * For GBS group: Inpatients with acute, progressive weakness and no alternative diagnosis, with onset less than 30 days prior to examination. * For control group: Hospitalized patients on the inpatient neurology service who are being treated for non-peripheral nerve disorders (e.g. epilepsy, multiple sclerosis, or stroke). * For all subjects: 18+ years of age Exclusion Criteria: \- Patients with any history of multifocal motor neuropathy (MMN), prior Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), or hereditary neuropathy (e.g. Charcot-Marie-Tooth)

What they're measuring

Internerve Variability of Cross-sectional Area (CSA) in Patients With GBS vs Controls

Timeframe: Day 0 and approximately 7 days after admission

Median Nerve Intranerve Cross-sectional Area (CSA) Variability in Patients With GBS vs Controls

Timeframe: Day 0 and approximately 7 days after admission

Ulnar Nerve Intranerve Cross-sectional Area (CSA) Variability in Patients With GBS vs Controls

Timeframe: Day 0 and approximately 7 days after admission

Trial details

NCT IDNCT04053452

SponsorDuke University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-04

Results submitted2025-03-18

View on ClinicalTrials.gov More Guillain-Barre Syndrome trials